Phathom Pharmaceuticals I... (PHAT)

NASDAQ: PHAT · Real-Time Price · USD

3.27

-1.02 (-23.78%)

At close: May 01, 2025, 12:06 PM

-23.78% (1D)

Bid	3.23
Market Cap	227.4M
Revenue (ttm)	55.25M
Net Income (ttm)	-334.33M
EPS (ttm)	-5.29
PE Ratio (ttm)	-0.62
Forward PE	-2.34
Analyst	Buy

Ask	3.32
Volume	1,999,560
Avg. Volume (20D)	1,197,539
Open	4.00
Previous Close	4.29
Day's Range	3.26 - 3.98
52-Week Range	3.26 - 19.71
Beta	0.35

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal re...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 25, 2019

Employees 427

Stock Exchange NASDAQ

Ticker Symbol PHAT

Website https://www.phathompharma.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 696.32% from the latest price.

Stock Forecasts

Earnings Surprise

New

Phathom Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $28.52M misses estimates by $501K, with 1391.58% YoY growth.

EPS of -1.07 misses estimates by 0.00, with 3.60% YoY growth.

Next Earnings Release

Phathom Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Just now New

Phathom Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

4 weeks ago

+7.23%

Phathom Pharmaceuticals shares are trading higher after Needham reiterated its Buy rating on the stock and maintained a $28 price target.

News

Just now · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago.

1 week ago · businesswire.com

Frazier Life Sciences Appoints Aditya Kohli to Partner

PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. ...

1 month ago · seekingalpha.com

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief ...

1 month ago · zacks.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.